Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Metabolic Dysfunction-Associated Steatohepatitis

Metabolic Dysfunction-Associated Steatohepatitis

Part of Metabolic Dysfunction-Associated Steatotic Liver Disease

Subtypes of Metabolic Dysfunction-Associated Steatohepatitis

Metabolic dysfunction-associated steatohepatitis (MASH) with significant fibrosis 1 Metabolic dysfunction-associated steatohepatitis cirrhosis 1 Non-cirrhotic metabolic dysfunction-associated steatohepatitis 1

27 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Metabolic Dysfunction-Associated Steatohepatitis

60 trials tracked for Metabolic Dysfunction-Associated Steatohepatitis: 4 in phase 3 or 4 and 2 with published results. The most-cited published study has 1008 citations.

60Trials tracked
4Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 4 2 Phase 3 2 Phase 2 45 Phase 1 3 Other / NA 8
  1. Phase 4 University of Texas H.S.C. San Antonio Pioglitazone in Non-Alcoholic Steatohepatitis Trial (UTHSCSA NASH Trial) Completed · 1,008 cited
  2. Phase 4 Prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) in Hispanics With Diabetes Mellitus Type 2 (T2DM) and Role of Treatment Completed · 313 cited
  3. Phase 3 Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis Completed
  4. Phase 3 Pentoxifylline/Nonalcoholic Steatohepatitis (NASH) Study: The Effect of Pentoxifylline on NASH Completed
  5. Phase 2 Phase 2a, Dose-ranging Study With PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD) Completed
  6. Phase 2 Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) Associated With Lipodystrophy Completed
Show 44 more trials
  1. Phase 2 Pentoxifylline in Patients With Nonalcoholic Steatohepatitis Completed
  2. Phase 2 A Study of IDN-6556 in Subjects With NAFLD and Raised Transaminases Completed
  3. Phase 2 A Double-blind Study to Assess 2 Doses of an Investigational Product for 16 Weeks in Participants With Non-alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus Completed
  4. Phase 2 Study of Pharmacodynamics and Safety of DGAT2i and ACCi Coadministered in Participants With Sponsor-defined Presumed Non Alcoholic Steatohepatitis Completed
  5. Phase 2 Ezetimibe Versus Placebo in the Treatment of Non-alcoholic Steatohepatitis Completed
  6. Phase 2 Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Participants With Nonalcoholic Steatohepatitis (NASH) Completed
  7. Phase 2 Study of Aldafermin (NGM282) in Subjects With Compensated Cirrhosis (ALPINE 4) Completed
  8. Phase 2 A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH) Completed
  9. Phase 2 Saroglitazar Magnesium in Patients With Nonalcoholic Fatty Liver Disease and/or Nonalcoholic Steatohepatitis Completed
  10. Phase 2 Study to Evaluate the Safety and Efficacy of Selonsertib, Firsocostat, Cilofexor, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) Completed
  11. Phase 2 A Phase 2 Study of Elobixibat in Adults With NAFLD or NASH Completed
  12. Phase 2 Open-Label Study To Evaluate MN-001 on HDL & Triglyceride in NASH & NAFLD Subjects Completed
  13. Phase 2 A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Liver Cirrhosis Completed
  14. Phase 2 A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001) Completed
  15. Phase 2 Saroglitazar Magnesium in the Treatment of Non-Alcoholic Steatohepatitis Completed
  16. Phase 2 BREATHID Octanoate Breath Test With or Without Methacetin Breath Test for Correlation With Biopsy in NASH Completed
  17. Phase 2 Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) Completed
  18. Phase 2 A Study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH) Completed
  19. Phase 2 Clinical Trial to Evaluate Efficacy of GR-MD-02 for Treatment of Liver Fibrosis in Patients With NASH With Advanced Fibrosis Completed
  20. Phase 2 CLINICAL PROTOCOL to Investigate the Long-term Safety and Efficacy of Metreleptin in Various Forms of Partial Lipodystrophy Completed
  21. Phase 2 A Clinical Trial to Evaluate the Efficacy and Safety of Two Aramchol Doses Versus Placebo in Patients With NASH Completed
  22. Phase 2 Study of Oral Idebenone to Treat Non-Alcoholic Steatohepatitis Completed
  23. Phase 2 Vitamin E and DHA-EE on NAFLD - Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial (PUVENAFLD) Completed
  24. Phase 2 Combination Obeticholic Acid (OCA) and Statins for Monitoring of Lipids (CONTROL) Completed
  25. Phase 2 A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis Completed
  26. Phase 2 Colesevelam Versus Placebo in the Treatment of Nonalcoholic Steatohepatitis Completed
  27. Phase 2 A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC-0602K in Patients With NASH Completed
  28. Phase 2 An Evaluation of the Safety and Efficacy of Nitazoxanide on Collagen Turnover in NASH Patients With Fibrosis Completed
  29. Phase 2 Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis. Completed
  30. Phase 2 Emricasan, an Oral Caspase Inhibitor, in Subjects With NASH Cirrhosis and Severe Portal Hypertension Completed
  31. Phase 2 A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis Completed
  32. Phase 2 Vitamin E Dosing Study Completed
  33. Phase 2 Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Participants With Liver Fibrosis Completed
  34. Phase 2 Aspirin for the Treatment of Nonalcoholic Fatty Liver Disease Completed
  35. Phase 2 A Study of HTD1801 in Adults With Nonalcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM) Completed
  36. Phase 2 Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH) Completed
  37. Phase 2 JKB-121 for the Treatment of Nonalcoholic Steatohepatitis Completed
  38. Phase 2 Safety, Tolerability, Pharmacokinetics and Efficacy of EYP001a in Patients With Nonalcoholic Steatohepatitis (NASH) Completed
  39. Phase 2 A Sub-study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH) Completed
  40. Phase 2 A Research Study on How Semaglutide Works in People With Fatty Liver Disease and Liver Damage Completed
  41. Phase 2 Study of ARO-HSD in Healthy Volunteers and Patients With Non-Alcoholic Steatohepatitis (NASH) or Suspected NASH Completed
  42. Phase 2 Phase II Trial of Silymarin for Non-Cirrhotic Patients With Non-Alcoholic Steatohepatitis Completed
  43. Phase 2 A Multiple Ascending Dose Study of Pegozafermin in Participants With Biopsy Confirmed Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) and at High Risk of NASH Completed
  44. Phase 1 A Study of Efinopegdutide in Participants With Hepatic Impairment (MK-6024-014) Completed

Showing the 50 most-cited and recently-updated of 60 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Phase 2 Trial Evaluating Zalfermin and Semaglutide Combinations for Metabolic Dysfunction Associated Steatohepatitis
Gastroenterology RCT
Phase 2 Trial Evaluating Zalfermin and Semaglutide Combinations for Metabolic Dysfunction Associated Steatohepatitis Trial Shows Semaglutide May Impact Liver Fibrosis in MASLD
A 52-week trial assessed whether zalfermin combined with semaglutide improves liver fibrosis in patients with advanced steatohepatitis.
A new trial suggests semaglutide may improve liver fibrosis in patients with MASLD, while other combinations did not show significant result…
Sep 2, 2026
rs2896019 G allele associated with 51% increased risk of MASLD susceptibility
Gastroenterology Meta-analysis
rs2896019 G allele associated with 51% increased risk of MASLD susceptibility Genetic variant linked to increased risk of fatty liver disease
This meta-analysis of 15028 adults identified the rs2896019 polymorphism (G allele) as a significant risk factor for MASLD. The study found …
A specific genetic marker may significantly increase the risk of developing and progressing to severe fatty liver disease.
Sep 1, 2026
AI, machine learning, and deep learning models facilitate multimodal diagnosis and prognosis in MASLD
Rheumatology Sys. Review
AI, machine learning, and deep learning models facilitate multimodal diagnosis and prognosis in MASLD Artificial intelligence helps identify and predict fatty liver disease
This scoping review synthesizes 73 studies regarding the role of AI, machine learning, and deep learning in diagnosing and predicting outcom…
New technology is helping doctors identify fatty liver disease and predict its progress by analyzing complex data and medical images.
Frontiers Aug 27, 2026
MicroRNAs influence lipid metabolism, inflammation, and fibrosis in nonalcoholic steatohepatitis progression
Genetics & Precision Medicine Sys. Review
MicroRNAs influence lipid metabolism, inflammation, and fibrosis in nonalcoholic steatohepatitis progression Small molecules called microRNAs may help track and treat liver disease
This systematic review examines the role of microRNAs (miRNAs) in the pathophysiology of nonalcoholic fatty liver disease. The authors synth…
New research highlights how tiny molecules called microRNAs influence liver inflammation and scarring, offering hope for better diagnosis an…
Frontiers Aug 6, 2026
Semaglutide improves MASH resolution (OR 3.48) and liver fat reduction in MASLD patients
Gastroenterology Meta-analysis
Semaglutide improves MASH resolution (OR 3.48) and liver fat reduction in MASLD patients Semaglutide helps resolve liver inflammation in patients with MASH
This meta-analysis of 1908 patients with MASLD and MASH found that semaglutide significantly improved MASH resolution (OR 3.48) and reduced …
New data shows semaglutide can reduce liver fat and inflammation for people with fatty liver disease, though results on scarring vary.
Aug 1, 2026
Proposed pathway for systematic MASLD/MASH assessment in type 2 diabetes
Diabetes & Endocrinology Sys. Review
Proposed pathway for systematic MASLD/MASH assessment in type 2 diabetes New Pathway Proposed to Manage Liver Disease in Diabetes Patients
This narrative review proposes a structured, risk-adapted outpatient pathway for MASLD/MASH assessment in patients with type 2 diabetes, sta…
A new proposed management plan aims to help people with type 2 diabetes identify and assess liver conditions more systematically.
Frontiers Jul 30, 2026
Subcutaneous semaglutide more than doubles the likelihood of NASH resolution without fibrosis progression
Gastroenterology Meta-analysis
Subcutaneous semaglutide more than doubles the likelihood of NASH resolution without fibrosis progression Semaglutide shows promise for treating fatty liver disease and NASH
This meta-analysis of randomized controlled trials evaluated subcutaneous semaglutide in adults with NAFLD or NASH. The analysis found signi…
A new analysis shows that semaglutide can help resolve liver inflammation and improve metabolic health in people with fatty liver disease.
NEJM Jul 26, 2026
Immune crosstalk between innate and adaptive compartments drives inflammatory mechanisms in MASLD and MASH progression
Gastroenterology Sys. Review
Immune crosstalk between innate and adaptive compartments drives inflammatory mechanisms in MASLD and MASH progression Immune system crosstalk drives fatty liver disease progression
This systematic review examines the role of immune system interactions in metabolic dysfunction-associated steatotic liver disease (MASLD) a…
A new review reveals that immune cells talking to each other may be what pushes fatty liver disease toward severe liver damage.
Frontiers Jun 30, 2026
Network meta-analysis ranks FGF21 analogs and SGLT2 inhibitors highest for MASH fibrosis
Diabetes & Endocrinology Meta-analysis
Network meta-analysis ranks FGF21 analogs and SGLT2 inhibitors highest for MASH fibrosis New analysis shows SGLT2 inhibitors may help liver scarring improve in adults with fatty liver disease
A network meta-analysis of 34 trials found FGF21 analogs and SGLT2 inhibitors ranked highest for improving liver fibrosis in MASH, with GLP-…
A large review of trials found SGLT2 inhibitors ranked highest for reducing liver scarring. These drugs also showed good safety and balanced…
Frontiers Jun 4, 2026
Narrative review explores immunometabolic networks in MASH and MASLD
Nutrition & Obesity Medicine Sys. Review
Narrative review explores immunometabolic networks in MASH and MASLD Future treatments for fatty liver disease may use personalized networks to guide care
This narrative review discusses metabolic dysfunction-associated steatohepatitis (MASH) and steatotic liver disease (MASLD), focusing on imm…
New ideas for treating fatty liver disease focus on personalized networks and multi-target approaches to guide future drug development.
Frontiers May 27, 2026
Narrative review explores macrophage reprogramming for liver fibrosis and MASH
Oncology Sys. Review
Narrative review explores macrophage reprogramming for liver fibrosis and MASH Scientists explore new ways to reprogram liver cells to heal damaged tissue and stop scarring
This narrative review summarizes macrophage reprogramming strategies for liver fibrosis and MASH. Approaches include gene modulation, pharma…
A recent review looks at fresh methods to change how liver immune cells behave. These changes could help heal liver scarring and improve hea…
Frontiers May 17, 2026
Review of triglyceride-lowering therapies for metabolic dysfunction-associated steatotic liver disease
Drug Pipeline Sys. Review
Review of triglyceride-lowering therapies for metabolic dysfunction-associated steatotic liver disease New Hope for Fatty Liver Disease Targets Hidden Triglyceride Problem
This narrative review synthesizes evidence on triglyceride-lowering therapies for metabolic dysfunction-associated steatotic liver disease. …
• Lowering triglycerides may directly heal fatty liver damage • Helps millions with metabolic syndrome and stubborn liver fat • Most treatme…
Frontiers May 12, 2026

Research across Metabolic Dysfunction-Associated Steatotic Liver Disease

Related studies from across the Metabolic Dysfunction-Associated Steatotic Liver Disease family.

Dioscin shows therapeutic potential for various liver disorders including MASLD and hepatocellular carcinoma
Drug Pipeline Sys. Review
Dioscin shows therapeutic potential for various liver disorders including MASLD and hepatocellular carcinoma Plant Compound Dioscin Shows Promise For Liver Disease
This systematic review evaluates the hepatoprotective effects and pharmacokinetics of Dioscin in various liver diseases. The review conclude…
A plant compound called Dioscin may help protect the liver, but human evidence is still missing and high doses carry risks.
Frontiers Sep 13, 2026
MASLD linked to 35% higher odds of HFpEF in pooled analysis of 899,629 patients
Cardiology Meta-analysis
MASLD linked to 35% higher odds of HFpEF in pooled analysis of 899,629 patients Liver Disease Linked to Higher Risk of Heart Failure
This meta-analysis of 3 studies (899,629 patients, 47,610 with MASLD) found that MASLD was associated with higher odds of clinically diagnos…
People with metabolic dysfunction-associated steatotic liver disease (MASLD) show a higher risk of developing heart failure with preserved e…
Sep 9, 2026
Ketogenic diets and intermittent fasting may improve weight, insulin sensitivity, and hepatic steatosis in MASLD
Psychiatry Sys. Review
Ketogenic diets and intermittent fasting may improve weight, insulin sensitivity, and hepatic steatosis in MASLD Ketogenic diets and fasting may improve liver health in patients
This narrative review examines the impact of ketogenic dietary interventions and intermittent fasting on patients with metabolic dysfunction…
New research suggests that ketogenic diets and intermittent fasting can help manage weight and liver fat in people with metabolic liver dise…
Frontiers Sep 8, 2026
Viral hepatitis infections pose significantly higher risk for liver cancer than smoking-related lung cancer
Oncology Meta-analysis
Viral hepatitis infections pose significantly higher risk for liver cancer than smoking-related lung cancer Comparing the risks of liver cancer from hepatitis versus lung cancer from smoking
This meta-analysis of 86,097,714 participants analyzed the relative risks of liver cancer from various exposures compared to lung cancer fro…
New data shows that certain hepatitis viruses pose a much higher risk for liver cancer than smoking does for lung cancer.
Sep 2, 2026
Efficacy of High-Intensity Interval Training and Moderate-Intensity Continuous Training in MASLD
Gastroenterology Meta-analysis
Efficacy of High-Intensity Interval Training and Moderate-Intensity Continuous Training in MASLD Exercise Types Improve Liver Health in MASLD Patients
Meta-analysis confirms that both HIIT and MICT significantly improve body composition, cardiometabolic markers, and liver function in MASLD …
High-intensity interval training and moderate continuous exercise both help MASLD patients. They improve body composition, metabolism, and l…
Sep 1, 2026
Telmisartan leads to modest fasting blood sugar reduction in patients with MASLD
Gastroenterology Meta-analysis
Telmisartan leads to modest fasting blood sugar reduction in patients with MASLD Telmisartan Shows Modest Effects on Blood Sugar in Liver Disease
This meta-analysis of 258 adults with MASLD found that telmisartan resulted in a modest reduction in fasting blood sugar of -2.78 mg/dL. Oth…
A review of clinical data suggests that the medication telmisartan may lower fasting blood sugar in adults with certain types of liver disea…
Sep 1, 2026
Clinical trials for MASLD show limited racial and ethnic diversity despite increasing Hispanic enrollment
Gastroenterology Meta-analysis
Clinical trials for MASLD show limited racial and ethnic diversity despite increasing Hispanic enrollment Clinical trials for fatty liver disease lack diversity
This meta-analysis of 91 randomized controlled trials evaluates racial and ethnic diversity in MASLD clinical trials. While Hispanic enrollm…
Most fatty liver disease trials underreport ethnicity, and Black patients are only 2.5% of participants, despite the disease's impact.
Sep 1, 2026
Fibrosis-informed markers provide a decision architecture for statin allocation in intermediate-risk MASLD patients
Rheumatology Guideline
Fibrosis-informed markers provide a decision architecture for statin allocation in intermediate-risk MASLD patients New guidelines help doctors choose statins for liver disease patients
This guideline proposes a decision-making framework for statin therapy in the intermediate-risk stratum for patients with MASLD. It utilizes…
Doctors now have a clearer way to decide who needs statin treatment when liver health and heart risk overlap.
Frontiers Aug 30, 2026
Phytochemicals modulate miRNA-mediated regulatory networks to influence metabolic reprogramming and cancer-associated signaling
Diabetes & Endocrinology Sys. Review
Phytochemicals modulate miRNA-mediated regulatory networks to influence metabolic reprogramming and cancer-associated signaling Phytochemicals May Influence RNA Networks Linked to Chronic Diseases
This narrative review explores how phytochemicals interact with miRNA-mediated regulatory networks through transcriptional, epigenetic, and …
New research explores how plant-based compounds might influence genetic switches that play a role in cancer and metabolic disorders.
Frontiers Aug 26, 2026
Empagliflozin reduces steatosis, fibrosis markers, and inflammatory indicators in preclinical models of MASLD
Drug Pipeline Meta-analysis
Empagliflozin reduces steatosis, fibrosis markers, and inflammatory indicators in preclinical models of MASLD Empagliflozin Shows Potential to Reduce Liver Fat and Fibrosis
This meta-analysis of 17 preclinical studies involving 584 animals indicates that empagliflozin significantly reduces steatosis and fibrosis…
Early research in animal models suggests that the medication empagliflozin may reduce liver fat, inflammation, and scarring in fatty liver d…
Frontiers Aug 24, 2026
Bidirectional virus-metabolism interaction in chronic hepatitis B and metabolic dysfunction-associated fatty liver disease
Allergy & Immunology Sys. Review
Bidirectional virus-metabolism interaction in chronic hepatitis B and metabolic dysfunction-associated fatty liver disease Liver disease and hepatitis B may fuel each other
This systematic review examines the interplay between viral infection and metabolic factors in patients with chronic hepatitis B and metabol…
Hepatitis B and fatty liver disease may worsen each other, raising liver cancer risk. New review explains the link.
Frontiers Aug 20, 2026
Dietary quality and precision nutrition may mitigate the vegetarian hepatoprotection paradox in MASLD patients
Gastroenterology Sys. Review
Dietary quality and precision nutrition may mitigate the vegetarian hepatoprotection paradox in MASLD patients Dietary Quality Matters More Than Labels for Fatty Liver Health
This narrative review explores how specific dietary components and genetic interactions influence hepatic lipid homeostasis in MASLD. The au…
Not all vegetarian diets are equal. New research suggests that specific ingredients and nutrient balances matter more than just removing mea…
Frontiers Aug 6, 2026

Questions about Metabolic Dysfunction-Associated Steatohepatitis

Can machine learning diagnose metabolic dysfunction-associated steatohepatitis and fibrosis?

Yes, machine learning models show good accuracy for diagnosing MASH and fibrosis, with pooled AUROCs around 0.83-0.84, but they are not yet ready to replace liver biopsy in clinical practice.

Full answer →
Which drugs work best for non-cirrhotic metabolic dysfunction-associated steatohepatitis?

For non-cirrhotic MASH, drugs targeting metabolism and insulin sensitivity (e.g., tirzepatide, semaglutide) work best, but lifestyle changes and weight loss are foundational.

Full answer →
Can lowering triglycerides help treat metabolic dysfunction-associated steatohepatitis?

Yes, lowering triglycerides may help treat MASH by reducing liver fat and improving inflammation, but more research is needed to confirm long-term benefits.

Full answer →

All Metabolic Dysfunction-Associated Steatohepatitis Articles